Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com

DALLAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring BioElectronics Corporation (Pink Sheets:BIEL - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision. The investment report on BioElectronics Corporation (Pink Sheets:BIEL - News) should be of particular interest to comparable healthcare products providers: Johnson & Johnson (NYSE:JNJ - News), Pfizer (NYSE:PFE - News) and Bayer Aktienges (Pink Sheets:...
Click here to read the whole Article (external link)

CEO Interview: Aeolus Pharmaceuticals, Inc. - John L. McManus

67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); Ne...
Click here to read the whole Article (external link)

Bayer Earnings Call scheduled for 10:00 am ET today

Live Call: Bayer Earnings Conference Call (Q3 2009) - Yahoo! Finance Copyright © 2009 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of ServiceCopyright © 2009 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ...
Click here to read the whole Article (external link)

Q3 2009 Bayer Earnings Release - 02:30 am ET

Earnings Announcements for Tuesday, October 27CompanySymbolTimeConferenceCall3M INDIA LTD3MINDIA.BOTime Not SuppliedA.M. Castle & CoCASBefore Market OpenListenAbaxis, Inc.ABAXAfter Market CloseABILITY ENTERPRISE2374.TW03:00 am ETAcadia Realty TrustAKRAfter Market CloseListenACE LimitedACEAfter Market CloseListenActelACTL4:15 pm ETListenADVANCED TECHNOLOGY & MATERIAL000969.SZTime Not SuppliedAdvent SoftwareADVSAfter Market CloseListenAEROSPACE COMMUNICATIONS HOLDING CO600677.SSTime Not SuppliedAGCOAGCOBefore Market OpenListenAIR CHINA LTDAICAF.PKTime Not SuppliedAK Steel Holding CorpAKS08:30 am ETAKER SEAFOODS ASAAKS.OL03:30 am ETAkzo Nobel N.V.AKZOF.PK02:00 am ETAlcon Inc.ACLAfter Market CloseListen...
Click here to read the whole Article (external link)

Buzzed Off At Bayer

A documentary on the declining population of bees worldwide is causing a migraine for German drug company Bayer.In Vanishing of the Bees, which opened in British theaters this month, beekeepers blame neonicotinoids, a class of pesticides produced by Bayer ( BAYRY.PK - news - people ), for so-called Colony Collapse Disorder. They theorize that neonicotinoids disrupt bees' navigational abilities, making them dizzy and unable to find their way back to the hive. There's more at stake than honey on your cereal. Without bee pollination, a third of the earth's food crops would fail. In the U.S., Bayer faces more bad buzz, including a recent backlash to deceptive ads for its One A Day vitamins. Bayer first claimed that the presence of selenium in the vitamins reduced the risk of prostate cancer. The company backed the claim with marginal proof from a dated health study. The company apparently ignored a more recent, seven-year, $118 million study funded by the National Institutes of Health, which determined that selenium doesn't prevent prostate cancer in healthy men--but it does cause diabetes in some. In June, the Center for Science in the Public Interest (CSPI), a nonprofit group focusing on food safety, demanded Bayer remove the anti-cancer claims on its packaging and recall the product. A day later, the FDA issued a letter stating it was "highly unlikely" selenium reduced the risk of prostate cancer. Last month, after Bayer failed to issue a recall, CSPI sued Bayer over its cancer claims. Bayer, in turn, threatened CSPI wi...
Click here to read the whole Article (external link)

Stocks: Quality Still Counts

Stocks: Quality Still Counts Shares of laggard companies outpaced those with strong financials in the latest stock market rally. That's about to change By Ben Levisohn The stock market has gained 58% since its bear-market low Mar. 9, but the rally hasn't lifted all equities equally. As is typical in many market bouncebacks, the worst recovered first. Low-quality companies, those with weak or nonexistent profits, mediocre return on equity, and less-than-stellar balance sheets, outpaced their more solidly profitable peers by nearly a 2-to-1 margin, according to research from Baird Private Wealth Management. Baird found that companies not earning a profit gained 92% from the Mar. 9 lows through the end of August, compared with a 47% rise for companies that had the highest profit margins. Companies with the lowest return on equity outperformed those with the highest by more than 2 to 1, according to Baird. But the data also show that this kind of low-quality rally is perfectly normal—and usually short-lived. For one thing, the profit-deficient companies suffered bigger price declines during the worst of the stock market tumult. The companies that were hit the hardest rally the most when it becomes clear they're not going away, but as the market normalizes, the rally will end. "Once this initial burst comes through, high quality emerges," says Aaron S. Reynolds, senior portfolio analyst at Baird. Buffett and Berkshire May Benefit Quality, however, is in the eye of the beholder. Adviser Steve Shueh of Roundview Capital in Princeton, N.J., is looking for top companies that will benefit as government support of the financial system is scaled back and fiscal stimulus ends—and private investment replaces public dollars. At the top of his list: Berkshire Hathaway (...
Click here to read the whole Article (external link)